Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | HTRA1 |
| Gene Name: | HTRA1 |
| Protein Full Name: | Serine protease HTRA1 |
| Alias: | L56;Serine protease 11 |
| Mass (Da): | 51287 |
| Number AA: | 480 |
| UniProt ID: | Q92743 |
| Locus ID: | 5654 |
| COSMIC ID: | HTRA1 |
| Gene location on chromosome: | 10q26.3 |
| Cancer protein type: | TSP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | INHIBITS |
| Number of cancer specimens: | 19625 |
| Percent of cancer specimens with mutations: | 0.52 |
| Gene undergoes hypermethylation: | in ovarian cancer |
| Normal role description: | Secreted protein. ATP-independent serine protease, that binds to TGF beta family members and acts as a repressor of TGF beta signalling, to which its proteolytic activity is closely connected. HTRA1 inhibits the EGRF/AKT signalling and thereby promotes anoikis, a form of cell death induced by detachment from the ECM. Expression downregulated in many types of cancers. In ovarian and gastric tumors, LOH and low expression are associated with poor chemotherapy response. |
| Commentary on involvement of protein in cancer: | No mutations have been reported on the Atlas of Genetics in Oncology or the SANGER COSMIC database. |